
ASMA (Anti Smooth Muscle Antibody) - IFA










The ASMA (Anti Smooth Muscle Antibody) - IFA test is a blood test used to detect the presence of autoantibodies (antibodies that mistakenly target an individual’s own cells and tissues) made against smooth muscle cells, often in the liver. This test helps in the diagnosis of autoimmune liver diseases, particularly autoimmune hepatitis (AIH). By identifying these antibodies, doctors can assess liver health and tailor appropriate treatment strategies.













Understanding ASMA (Anti Smooth Muscle Antibody) - IFA
Anti-smooth muscle antibodies (ASMA) attack the liver's smooth muscle tissue cells and are primarily associated with autoimmune diseases like autoimmune hepatitis (AIH). However, these antibodies can be found in diseases like infectious mononucleosis, rheumatic diseases, and different types of cancer.
The presence of ASMA in the blood is a critical marker in the diagnosis of autoimmune hepatitis (AIH). AIH occurs when the antibodies attack the liver, causing inflammation and damage. It can exhibit late onset and can mimic viral hepatitis symptoms like fatigue, nausea, vomiting, joint and abdominal pain, jaundice, dark urine, and pale stools. It can also present with non-specific symptoms such as fatigue, weight loss, and diarrhea which could be associated with other liver diseases, or be discovered incidentally through abnormal liver function tests (LFT). AIH should be considered when no other clear diagnosis is reached. The ASMA (Anti Smooth Muscle Antibody) - IFA test also helps detect other autoimmune liver diseases like primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), though different autoantibodies are primarily associated with these conditions.
The ASMA (Anti Smooth Muscle Antibody) - IFA test detects Immunoglobulin G (IgG) antibodies targeting actin filaments in smooth muscle cells using the sensitive, gold standard indirect immunofluorescence Assay (IFA) method. If ASMAs are present, they bind to their target antigen in the tissue sample. Subsequently, a fluorescent dye such as fluorescein isothiocyanate (FITC) is then added which highlights the presence of ASMA in the form of a distinctive pattern of fluorescence under the fluorescent microscope.
This test is meant for screening purposes only and is not intended as a standalone test. It should be used in conjunction with clinical evaluation and other laboratory tests, including liver function test (LFT), liver biopsies, etc, to make a definitive diagnosis.
An overnight fasting (8 to 12 hours) is preferred before the ASMA (Anti Smooth Muscle Antibody) - IFA. However, drinking water is acceptable. Also, it is important to refrain from alcohol consumption the day before the test. Inform your doctor about all the medicines and supplements that you may be taking, as some of them may affect the test results and may need to be adjusted or temporarily discontinued before the test.
Test result ranges may vary across different laboratories. Abnormal test results require an expert interpretation, therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for proper understanding of the test results.
What does ASMA (Anti Smooth Muscle Antibody) - IFA measure?
The ASMA (Anti Smooth Muscle Antibody) - IFA test measures the levels of anti-smooth muscle antibodies (ASMA) in the blood. These antibodies primarily target the smooth muscle cells within the body, particularly those found in organs like the liver. The presence of these antibodies in the blood indicates an autoimmune activity, particularly in conditions like autoimmune hepatitis (AIH) where the immune system of the body mistakenly attacks the liver cells. Additionally, the ASMA (Anti Smooth Muscle Antibody) - IFA test may be used to detect other autoimmune liver conditions such as primary biliary liver cirrhosis (PBC) and to distinguish between various liver disorders with similar symptoms. This screening test helps in the early detection and timely initiation of treatment against autoimmune hepatitis to prevent further damage to the liver.





FAQs related to ASMA (Anti Smooth Muscle Antibody) - IFA
- Autoimmune Hepatitis [Internet]. USA: NIDDK; Apr.2023 [Accessed 27 Mar. 2024]. Available from:
- Autoimmune Hepatitis [Internet]. Rochester, NY: University of Rochester Medical Center; [Accessed 27 Mar. 2024]. Available from:
- Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice. Clin Rev Allergy Immunol. 2022 Oct;63(2):124-137. [Accessed 27 Mar. 2024]. Available from:
- Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance. Front Immunol. 2018 Mar 27;9:609. [Accessed 27 Mar. 2024]. Available from:
- Mercado LA, Gil-Lopez F, Chirila RM, Harnois DM. Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview. Diagnostics (Basel). 2024 Feb 9;14(4):382. [Accessed 27 Mar. 2024]. Available from:
- Zamanou A, Tsirogianni A, Terzoglou C, Balafas A, Economidou I, Lymberi P. Anti-smooth muscle antibodies (ASMAs) and anti-cytoskeleton antibodies (ACTAs) in liver diseases: a comparison of classical indirect immunofluorescence with ELISA. J Clin Lab Anal. 2002;16(4):194-201. [Accessed 27 Mar. 2024]. Available from:
- Zhang WC, Zhao FR, Chen J, Chen WX. Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis. PLoS One. 2014 Mar 20;9(3):e92267. [Accessed 27 Mar. 2024]. Available from:
- Muratori P, Muratori L, Agostinelli D, Pappas G, Veronesi L, Granito A, Cassani F, Terlizzi P, Lenzi M, Bianchi FB. Smooth muscle antibodies and type 1 autoimmune hepatitis. Autoimmunity. 2002 Dec;35(8):497-500. [Accessed 27 Mar. 2024]. Available from:
- DermNet NZ. Indirect immunofluorescence [Internet]. [Accessed 27 Mar. 2024]. Available from:
- Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice. Clin Rev Allergy Immunol. 2022 Oct;63(2):124-137. [Accessed 27 Mar. 2024]. Available from:
Other tests
- LFT (Liver Function Test)
- LFT and KFT (Liver Function Test & Kidney Function Test)
- PT INR (Prothrombin Time with INR)
- HIV 1 and 2 Antibody, Rapid Screening Test
- Hepatitis B Surface Antigen (HBsAg), Rapid Screening Test
- Viral Marker Screening (HIV, HBsAg, Anti-HCV)
- Hepatitis C Antibody (HCV), Rapid Screening Test
- Total IgE
- Rheumatoid Factor - Quantitative
- Serum Electrolytes
- CBC (Complete Blood Count)
- FBS (Fasting Blood Sugar)
- Thyroid Profile Total (T3, T4 & TSH)
- HbA1c (Glycosylated Hemoglobin)
- PPBS (Postprandial Blood Sugar)
- Lipid Profile
- Vitamin D (25-Hydroxy)
- Urine R/M (Urine Routine & Microscopy)
- Coronavirus Covid -19 test- RT PCR
- LFT (Liver Function Test)
- KFT (Kidney Function Test)
- TSH (Thyroid Stimulating Hormone) Ultrasensitive
- ESR (Erythrocyte Sedimentation Rate)
- Uric Acid, Serum
- Vitamin B12
- CRP (C-Reactive Protein), Quantitative
- Urine C/S (Urine Culture and Sensitivity)
- Serum Electrolytes
- Serum Calcium
- Serum Creatinine
- Diabetes Screening (HbA1C & Fasting Sugar)
- KFT with Electrolytes (Kidney Function Test with Electrolytes)
- Cholesterol - Total
- Hb (Hemoglobin)
- Complete Hemogram (CBC & ESR)



















